Back to Search

MARK WITTMAN, MD

MD

Critical Care Medicine (Anesthesiology) Physician

NPI: 1295723708IndividualAccepts Medicare

Specialties, Licenses & Credentials

Emergency Medicine Physician

Emergency Medicine

Code: 207P00000X

G45108(CA)
Critical Care Medicine (Anesthesiology) PhysicianPrimary

Anesthesiology — Critical Care Medicine

Code: 207LC0200X

G45108(CA)
Anesthesiology Physician

Anesthesiology

Code: 207L00000X

G45108(CA)

CMS Specialties

PrimaryCRITICAL CARE (INTENSIVISTS)

Additional

ANESTHESIOLOGY

Education

NORTHWESTERN UNIVERSITY FEINBERG MEDICAL SCHOOL

Class of 1980

Research & Publications (15)

Novel 1H-(benzimidazol-2-yl)-1H-pyridin-2-one inhibitors of insulin-like growth factor I (IGF-1R) kinase.
PMID 17187980·Bioorg Med Chem Lett·2007
7-preclinical
Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity.
PMID 16134929·J Med Chem·2005
7-preclinical
Synthesis and antitumor activity of novel paclitaxel-chlorambucil hybrids.
PMID 11277526·Bioorg Med Chem Lett·2001
7-preclinical
Synthesis of metabolically blocked paclitaxel analogues.
PMID 11277525·Bioorg Med Chem Lett·2001
8-other
Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity.
PMID 18763755·J Med Chem·2008
7-preclinical
Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.
PMID 18572407·Bioorg Med Chem Lett·2008
8-other
2-(1H-Imidazol-4-yl)ethanamine and 2-(1H-pyrazol-1-yl)ethanamine side chain variants of the IGF-1R inhibitor BMS-536924.
PMID 18258427·Bioorg Med Chem Lett·2008
7-preclinical
Thyroxine increases the rate but does not alter the pattern of innervation during embryonic chick corneal development.
PMID 18172086·Invest Ophthalmol Vis Sci·2008
7-preclinical
Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile.
PMID 17398093·Bioorg Med Chem Lett·2007
7-preclinical
Discovery and initial SAR of 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-ones as inhibitors of insulin-like growth factor 1-receptor (IGF-1R).
PMID 17317169·Bioorg Med Chem Lett·2007
8-other
Challenges in the development of mGluR5 positive allosteric modulators: the discovery of CPPHA.
PMID 17210250·Bioorg Med Chem Lett·2007
7-preclinical
In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417.
PMID 16397250·Cancer Res·2006
7-preclinical
Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor.
PMID 15867374·Cancer Res·2005
7-preclinical
Synthesis and antitumor activity of novel C-7 paclitaxel ethers: discovery of BMS-184476.
PMID 11741476·J Med Chem·2001
8-other
Insulin sensitivity and beta-cell secretion after liver transplantation in patients with acute liver failure.
PMID 11406252·Transplant Proc·2001
4-observational

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Contact & Hours

Address
120 S SPALDING DR, STE. #301
BEVERLY HILLS, CA 90212

Location

Practice Location

120 S SPALDING DR, BEVERLY HILLS, CA
(310) 385-7755

Quick Facts

NPI
1295723708
Entity Type
Individual
Gender
Male
Medicare
Accepted
Specialties
3
Locations
1
Years in Practice
46
Publications
15

Are you this provider?

Claim Your Profile